Evaxion A/S has announced significant advancements in its AI-Immunology™ platform, introducing a new automated vaccine design module that streamlines and enhances the vaccine development process. The upgraded platform now enables automated vaccine design for both new and existing vaccines, aiming to boost quality and dramatically reduce development time from months to days. According to the company, this innovation addresses key challenges of manual vaccine design, such as ensuring proper antigen expression and conformation, and offers substantial cost savings. Evaxion will present detailed validation data on these improvements at the upcoming World Vaccine Congress Europe in Amsterdam on October 15, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-006342), on October 08, 2025, and is solely responsible for the information contained therein.